Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Equity Average (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Equity Average for 5 consecutive years, with $158.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 403.51% year-over-year to $158.3 million, compared with a TTM value of $158.3 million through Dec 2025, up 403.51%, and an annual FY2025 reading of $88.7 million, up 113.12% over the prior year.
  • Equity Average was $158.3 million for Q4 2025 at SAB Biotherapeutics, up from $88.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $158.3 million in Q4 2025 and bottomed at $16.7 million in Q2 2025.
  • Average Equity Average over 5 years is $43.2 million, with a median of $36.7 million recorded in 2021.
  • Peak annual rise in Equity Average hit 403.51% in 2025, while the deepest fall reached 66.22% in 2025.
  • Year by year, Equity Average stood at $36.8 million in 2021, then decreased by 16.23% to $30.8 million in 2022, then increased by 17.63% to $36.3 million in 2023, then fell by 13.35% to $31.4 million in 2024, then surged by 403.51% to $158.3 million in 2025.
  • Business Quant data shows Equity Average for SABS at $158.3 million in Q4 2025, $88.5 million in Q3 2025, and $16.7 million in Q2 2025.